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improving outcomes [4] . There are a number of reports of viral clearance following infusion of unmanipulated donor leucocytes or of selected adenovirus-specific T cells [5, 6] and following reduction or discontinuation of immune suppression, confirming that reconstitution of antiviral immunity is likely critical to favorable outcome [7] [8] [9] .
The incidence of adenovirus infection and disease remains unclear. In adult cohorts, rates ranging from 2% to 27% have been reported, with associated mortality rates of 6%-86% [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] . Much of this variation is due to differing definitions of infection and disease. The variation also reflects the variety of diagnostic techniques used and whether cases were reported based on clinical symptoms and signs or on routine surveillance. Increased rates have been reported following reduced intensity conditioning (RIC) transplant protocols that use in vivo T-cell depletion, usually with alemtuzumab. The incidence here has been reported as 18.4%, with an associated mortality of 45.5% and a quoted overall probability of adenoviral-associated death of 8.8% [18] . This would clearly represent a major contributor to transplant-related mortality using these conditioning strategies.
We therefore instituted a weekly surveillance program for adenoviremia using quantitative polymerase chain reaction (qPCR). Here we present the results from all HSCT receiving in vivo alemtuzumab.
METHODS

Patients and Viral Surveillance
In January 2008 we initiated a surveillance program for patients undergoing allogeneic HSCT based upon weekly qPCR of plasma for adenovirus, cytomegalovirus (CMV), and Epstein-Barr virus. Quantitative real-time PCR for adenovirus DNA was performed using the method described by Heim et al [21] with minor modifications; this method can detect all 51 adenovirus types. Stool samples were screened for adenovirus in those with diarrhea lasting longer than 48 hours (24 hours for inpatients) and nasopharyngeal swabs in those with coryzal symptoms. The same PCR method was used for all these samples but without quantitation. Surveillance continued until day 100. It was felt that there was no significant ongoing risk of infection, but surveillance was restarted if clinically indicated (eg, following enhanced immune suppression for graft-vs-host disease [GvHD] ).
This analysis was restricted to patients receiving a regimen incorporating in vivo T-cell depletion using alemtuzumab, either FM-C (fludarabine/melphalan/alemtuzumab) or BEAM-C (carmustine/etoposide/cytarabine/melphalan/alemtuzumab) [22, 23] . Ciclosporin (CsA) was started on day −1 as prophylaxis against GvHD, with additional immunosuppressive drugs given for treatment of GvHD, as required. Routine antimicrobial prophylaxis included 200 mg aciclovir by mouth 3 times a day to prevent herpes simplex virus and varicellazoster virus infection. Patients with less than 28 days of followup were excluded.
Treatment of Adenovirus Infection
Reduction or withdrawal of immunosuppression was attempted where possible in those with viral titers of >10 000 copies/mL. Treatment with cidofovir was initiated either if adenoviral disease was suspected (usually hepatitis or pneumonitis) or if a rising titer of >50 000 copies/mL was detected, although specific thresholds were not stipulated in advance and treatment decisions were made by the attending clinicians. Intravenous immune globulin was not given.
Statistical Analysis
Data were analyzed according to published guidelines for assessment of outcomes after transplantation [24] . Timeto-event outcomes with competing risks (ie, incidence of adenoviremia or isolation from other sites) were estimated as cumulative incidence curves with death without viral detection as a competing risk. Survival curves were estimated according to the Kaplan-Meier method, and comparisons made using the log-rank method. Further statistical comparisons were performed using the Fisher exact test, t test, or Mann-Whitney U test, as appropriate. P values <.05 were considered significant.
RESULTS
Study Population
Between January 2008 and January 2011, 120 patients received T-cell-depleted RIC allografts, of whom 116 had >28 days of follow-up (4 early nonrelapse-related mortality without adenoviremia). Median age was 41 years (range, 15-66 years). Median follow-up in surviving patients was 2.2 years (range, 0.9-4.0 years). Patient characteristics are listed in Table 1 .
Incidence by Surveillance Blood PCR
Fourteen of the 116 patients (cumulative incidence 12.1% [95% confidence interval (CI), 7.4%-19.8%]) developed adenoviremia with a titer above the limit of quantitation (200 copies/mL) on at least 1 occasion ( Figure 1A ). The median time to first detectable titer was 28 days after HSCT (range, 10-347 days) and median time to the maximum titer was 49 days (range, 16-368 days). An additional 10 patients developed adenoviremia at levels below the limit of quantitation, giving a cumulative incidence of 20.8% (95% CI, 14.6%-29.7%). These 10 cases are not considered further unless specifically indicated.
Risk Factors for Adenoviremia
Univariate analysis was performed to assess risk factors for detection of adenovirus, looking at both baseline characteristics and clinical course. Donor type (unrelated or sibling) or conditioning regimen had no effect on the likelihood of adenovirus detection (Table 1 ). Diagnosis (lymphoid > myeloid) and recipient CMV serostatus ( positive > negative) were both significantly correlated with adenoviremia. None of the factors examined in the clinical course showed a significant effect (CMV infection, time to neutrophil recovery, maximum GvHD grade, or use of systemic immunosuppression in addition to CsA).
Positive PCR Results From Other Sites
Stools were examined in 106/116 (91.4%) and nasopharyngeal swabs were examined in 99/116 (85.3%) patients on at least 1 occasion; adenovirus was detected in 9 (8.5%) stool and 7 (7.1%) nasopharyngeal samples. Nine patients had conjunctival swabs tested, of which 1 was positive (11.1%). Of the 14 patients with adenoviremia, 8 also tested positive for adenovirus from 1 or more other sites, including stool in 7, respiratory secretions in 3, and conjunctival swab in 1 ( Table 2 ). All occurred within 7 days of a positive blood PCR result. Three of the 10 patients with adenoviremia below the threshold for quantification also had adenovirus detected by PCR from other sites (2 respiratory, 1 stool), as did 3 patients who never had detectable adenoviremia (2 respiratory, 1 stool). None of these latter 6 patients received adenovirus-specific treatment, and symptoms subsequently resolved. The cumulative incidence of adenoviremia >200 copies/mL or adenoviral detection at other sites (n = 20) was 17.4% (95% CI, 11.7%-25.9%; Figure 1B ).
Clinical Course of Patients With Adenoviremia
Details for patients with adenoviral titers >200 copies/mL are shown in Table 2 . Eight of the 14 patients had levels <10 000 copies/mL. In these cases no specific interventions were undertaken. Viral titers remained >200 copies/mL for up to 4 weeks, though peak levels of >1000 copies/mL were only documented for 1-2 weeks. No attempts were made to modulate immune suppression based on the adenoviral titers in these cases.
In 1 patient (case 9) the viral titer peaked at 48 000 copies/ mL after 10 days. The patient had coincident CMV infection treated with ganciclovir and was receiving systemic steroids for GvHD. Adenoviral titers fell after reduction in steroid dose and became undetectable within 3 weeks.
The remaining 5 patients (4% of the total cohort) had peak titers of 99 000-2 500 000 copies/mL and all received cidofovir (cases [10] [11] [12] [13] [14] . The temporal profiles of viremia are illustrated in Figure 2 . Three were receiving enhanced immune suppression to treat GvHD at the time of adenoviremia, and 1 had extensive chronic GvHD treated previously with steroids. Attempts were made to reduce immune suppression in all patients. The most protracted infection occurred in a patient in whom this was most difficult. This patient received infliximab for grade III gastrointestinal GvHD, which was steroid responsive but recrudesced on dose reduction. Further attempts to wean steroid were limited by episodes of diarrhea. This patient received 10 doses of cidofovir before clearing the virus, after the prednisolone dose had been weaned to 5 mg once daily. Three of the other 4 patients also successfully cleared virus after 1-3 doses of cidofovir in combination with a reduction in immune suppression. This included 1 patient in whom a pneumonitis thought to be causally associated with adenovirus occurred (case 10, who also received a dose of tenofovir).
Case 11 underwent unrelated donor HSCT for mantle cell lymphoma. Renal impairment limited the tolerable dose of CsA, and mycophenolate mofetil was therefore given as additional GvHD prophylaxis. Isolated episodes of adenoviremia with titers >200 copies/mL were noted on day 33 and day 54 posttransplant, associated with prolonged episodes of CMV viremia. Adenoviremia became detectable again on day 89 with minimal change during the following week, then a rapid rise from 1000 copies/mL to 2 500 000 copies/mL occurred during the next week. Despite withdrawal of immune suppression and institution of cidofovir, the patient developed pneumonitis and a coincident rise in CMV titer. Although this period was associated with a rapid expansion of lymphocytes from 0.01 × 10 9 /L to 0.52 × 10 9 /L, the patient suffered an asystolic arrest. Both adenovirus and CMV were implicated as contributing to the death.
Overall survival of patients with adenoviremia of >200 copies/mL was comparable to that of those without ( Figure 1C ; 64.9% vs 70.7% at 3 years, P = .79), as was that of those with adenoviremia or isolation of adenovirus from other sites compared with those without (Figure 1D ; 63.7% vs 71.0% at 3 years, P = .73).
DISCUSSION
The clinical impact of adenoviral infection following HSCT in adults remains contentious. Reports of adenovirus infection and disease (Table 3 ) reveal a wide variation in both incidence and mortality [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] . Much of this difference relates to study methodology, which can be divided broadly between case Figure 1 . Incidence of viremia and overall survival. A. Cumulative incidence of adenoviremia. B, Cumulative incidence of adenoviremia with polymerase chain reaction (PCR) >200 copies/mL or adenovirus isolated from other site. C, Overall survival according to adenoviremia. D, Overall survival according to adenoviremia with PCR >200 copies/mL or adenovirus isolated from other site. finding and surveillance. Case-finding studies or ad hoc screening would likely miss low-level viremia and, by selecting for cases with symptomatic disease, are more likely to identify adenovirus as apparently contributing to mortality.
Detection of adenovirus in nonblood tissues ( primarily urine, stool, and respiratory secretions) was previously the mainstay of diagnosis. However, the correlation between these assays and systemic disease is not fully characterized, Figure 2 . A-E, Clinical course of the 5 patients treated with systemic antiadenoviral drugs. Patient details (cases 10-14) are as described in Table 2 . Continuous line, blood adenovirus titer; dashed line, absolute lymphocyte count; black arrow, treatment with cidofovir; white arrow, treatment with tenofovir. although detection of adenovirus in stool and nasopharyngeal aspirate has been shown to often be a precursor to systemic disease [25, 26] . The increased availability of PCR-based technology for routine screening might be expected to increase the apparent incidence of adenoviral infection and also reduce associated mortality. Protocols incorporating in vivo T-cell depletion are reported to associate with increased rates of adenovirus infection and mortality [11, 18] . Avivi et al described 86 patients who received the FM-C regimen with an 18.4% adenovirus infection rate following symptom-directed investigation (largely culture based) with an associated mortality of 45.5% (5/11), which equated to an adenovirus-associated nonrelapse-related mortality risk of 8.8% for the entire cohort [18] . Our data, in contrast, suggest that adenoviral infection is not such a significant problem despite the use of alemtuzumab-containing conditioning protocols. In particular, adenovirus was felt to be contributory to only 1 patient death in the current study (a cumulative incidence of only 0.9% of the entire cohort, or 7% of those with adenoviremia) and as such not to have a major impact on nonrelapse mortality or overall posttransplant outcomes. It is important to recognize that both of these studies, and the majority of studies reported in the literature, are based on relatively small patient numbers and that the associated low event rates for adenoviral-associated mortality mean that confidence intervals are broad. The 95% confidence intervals are 0.1%-6.1% in our study compared with 2%-16% in the study of Avivi et al. It remains possible, therefore, that the true incidence lies somewhere in between. It is tempting, however, to speculate that the apparently lower rate in our study reflects changes in practice in terms of the management of adenoviral infection, particularly because surveillance may allow earlier modulation of immune suppression and pharmacological intervention with antiviral drugs. The median time to adenoviral detection was 28 days in the current study compared with 90 days in the Avivi et al study, in which interventions were less standardized.
The majority of episodes in our study were self-limiting, particularly those with viral titers of <10 000 copies/mL. Five of the 6 with higher titers responded to modulation of immune suppression with or without the addition of cidofovir. Therapy was most prolonged in the patient in whom modulation of immune suppression was most problematic, suggesting that although cidofovir may have been an important contributor in the control of viral infection, reduction in immune suppression is the critical component to overall resolution. In this regard it is interesting that the only adenoviralassociated death occurred in a patient in whom the titer rose most rapidly. Rapidly increasing or sustained adenoviremia is reported to be associated with development of severe disease [25, 27, 28] . Although cessation of immune suppression resulted in a significant rise in lymphocyte count, coincident CMV viremia and rapidly progressive pneumonitis despite cidofovir may have provided insufficient time for adenoviral clearance. It is unclear whether any other strategy could have altered the eventual outcome. More frequent assessment of viral load would have to be targeted to all patients with quantifiable viremia if the aim was to allow more rapid institution of therapy, and practically it would only have allowed antiviral therapy to be started 3-4 days earlier. Conversely, more aggressive intervention with cidofovir at lower viral titers would lead to unnecessary exposure of the majority of treated patients to significant renal toxicities. A cellular therapeutic would likely need to be manufactured on an ad hoc basis due to the low incidence of problematic adenoviral infection, introducing a clinically significant time delay. It remains unclear whether such a product would have been any more effective than reduction in immune suppression in our patient given the impressive expansion of endogenous lymphocytes.
With regard to risk factors for adenoviremia, it is notable that neither GvHD nor enhanced immune suppression per se correlated with higher overall risk ( Table 1 ). It is possible that this reflects the relatively high levels of low-level viremia detectable by PCR following T-cell depletion. With such a level of background noise, the impact of further immune suppression would be harder to detect. Considering only patients with >5000 copies/mL, 6 of 7 had received enhanced immune suppression compared with 39 of the other 109 patients (P = .01), suggesting that higher levels of viremia may be more common in such patients, that is, that adenoviral infection is clinically more problematic in those receiving enhanced immune suppression. The associations with underlying diagnosis and CMV serostatus were more striking. The higher incidence in those with lymphoid disorders could reflect the greater immune suppression that is inherently associated with many of these disorders combined with more lymphocytotoxic chemotherapies prior to transplantation. The association between CMV and adenoviral infections has been recognized for some time, and it is likely that reduced T-cell function would predispose to both. The association, however, seems more complex than this. For example, the CMV major immediate early promoter can be transactivated by adenovirus early proteins, suggesting that adenovirus expression can activate quiescent CMV sequences [29] . Conversely, the reciprocal heterologous activation can also occur [30] , inferring that CMV early proteins might activate quiescent adenoviral sequences. Cidofovir is therefore an attractive agent to use therapeutically because it has activity against both viruses.
One question that arises is, how broadly applicable are the findings to other transplant settings? It is generally accepted that adenoviral infections are more problematic in pediatric cohorts and following cord blood transplants. In these cases, issues such as greater exposure and the lack of transference of cross-reactive memory T-cell populations from virus-naïve donors are likely relevant, and additional T-cell depletion may still prove detrimental. Nevertheless, pediatric patients receiving alemtuzumab also responded to withdrawal of immune suppression and antiviral drugs in a recent study [31] . Furthermore, the incidence of adenoviremia in those receiving alemtuzumab was remarkably similar (19%) to the incidence in the current study, as was the adenovirus-associated mortality (1/64 = 1.6%), suggesting that in the setting of prospective surveillance, pediatric and adult cohorts may be more similar than previously recognized. The use of antithymocyte globulin results in less profound T-cell depletion than with alemtuzumab, more rapid T-cell reconstitution, and greater levels of GvHD. By contrast, other methods of T-cell depletion, such as ex vivo selection, can result in more profound T-cell depletion. Although the method of T-cell depletion did not seem to influence the incidence of adenoviremia in a pediatric cohort, mortality was closely linked with the absence of lymphocyte recovery, appearing more likely when the graft was T-cell depleted using CD34-directed magnetic sorting [31] .
It is difficult to make definitive statements regarding cost/ benefit analyses from studies such as ours. Some of the major costs associated with surveillance strategies relate to sampling, transport, and processing, which incur no additional costs when performed in parallel with weekly PCR-based surveillance for CMV. Arguably, cost savings are enabled by a reduction in treatment of those cases where adenovirus is detected in nonblood sites due to symptom-based screening but either at low levels or not at all in plasma. However, a targeted screening program might prove equally effective. More significant, 2 patients with high viral loads (>90 000 copies/mL) did not have virus detected in nonblood sites. Such patients may be uncommon, but early intervention may reduce subsequent patientsupport costs by preventing more serious clinical complications and perhaps also associated mortality. Because the costs associated with these rare events are high, they may offset the cost of a screening program. Further investigation is warranted.
In summary, our data indicate that adenoviral infection is not as common a clinical problem following alemtuzumabbased reduced-intensity HSCT in adult patients as previously indicated. Adenoviremia was transient in the majority of patients and did not require specific intervention. In the minority of patients who received active treatment, cidofovir appeared to effectively control viremia in most cases, allowing time for the impact of reduced immune suppression to apparently enable reconstitution of endogenous antiviral immunity. However, a more detailed evaluation of reconstitution of adenovirus-specific immunity is warranted. The results require confirmation in larger patient cohorts, and future studies should focus on the standardization of definitions for disease and infection and of detection methods.
Notes
